XML 52 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense
The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our condensed consolidated statements of operations (in thousands):
Three Months Ended March 31,
20252024
(unaudited)
Restricted stock units$5,525 $8,343 
Performance-based restricted stock units1,165 213 
Employee stock purchase plan284 300 
Restricted shares569 1,969 
Options— 13 
Total stock-based compensation$7,543 $10,838 
Three Months Ended March 31,
20252024
(unaudited)
Cost of revenue$1,221 $1,697 
Sales and marketing2,162 3,990 
Research and development1,133 1,844 
General and administrative3,027 3,307 
Total stock-based compensation$7,543 $10,838 
Schedule of Information Related to Stock Options A summary of the share option activity under the 2019 Plan for the three months ended March 31, 2025, is as follows:
Time-Based Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Life in YearsAggregate Intrinsic Value
(unaudited)
Outstanding at January 1, 2025
1,053,251 $11.99 
Options cancelled/expired
(30,209)10.53 
Outstanding at March 31, 2025
1,023,042 $12.03 2.9$— 
Vested and expected to vest as of March 31, 2025
1,023,042 $12.03 2.9$— 
Vested and exercisable as of March 31, 2025
1,023,042 $12.03 2.9$— 
Schedule of Outstanding RSUs and Related Activity The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2025:
Restricted Stock UnitsWeighted Average Grant Date Fair Value
(unaudited)
Unvested and outstanding at January 1, 2025
3,505,406 $11.49 
RSUs granted3,226,619 4.95 
RSUs vested(747,148)11.93 
RSUs forfeited(277,081)8.27 
Unvested and outstanding at March 31, 2025
5,707,796 $7.76 
The following table sets forth the outstanding PRSUs, including executive PRSUs with market-based tranches, and related activity for the three months ended March 31, 2025:
Performance-based Restricted Stock UnitsWeighted Average Grant Date Fair Value
(unaudited)
Unvested and outstanding at January 1, 2025
524,313 $9.90 
PRSUs granted2,401,883 4.98 
PRSUs vested(146,734)9.82 
PRSUs forfeited(51,579)10.28 
Unvested and outstanding at March 31, 2025
2,727,883 $5.56 
Schedule of Fair Value Measurement Inputs and Valuation Techniques The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs used during the three months ended March 31, 2025:
Valuation MethodMarket Price of Revenue RiskRevenue VolatilityExpected Term (years)Risk-free interest rate
(unaudited)
Revenue-based earn-out liabilities
Monte Carlo
13.0%40%1.94.3%
The fair value of the market-based tranches included in the executive PRSUs were estimated on the date of grants using the Monte Carlo simulation valuation model with the following assumptions for the three months ended March 31, 2025 and 2024:
Three Months Ended
March 31, 2025
Three Months Ended
March 31, 2024
(unaudited)
Expected volatility71.6%65.5%
Expected term (in years)
1-3
1-3
Risk-free interest rate
4.16% - 4.23%
4.33% - 4.91%
Expected dividends
Schedule of Employee Stock Purchase Plan
The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
(unaudited)
Expected volatility
75.2%
55.5%
Expected term (in months)66
Risk-free interest rate
4.25%
5.24%
Expected dividends